159 related articles for article (PubMed ID: 12439929)
1. Detection of soluble TRAIL in HBV infected patients and its clinical implications.
Han LH; Sun WS; Ma CH; Zhang LN; Liu SX; Zhang Q; Gao LF; Chen YH
World J Gastroenterol; 2002 Dec; 8(6):1077-80. PubMed ID: 12439929
[TBL] [Abstract][Full Text] [Related]
2. [Soluble tumor necrosis factor related apoptosis inducing ligand (sTRAIL) and clinical outcome of HBV infection in human].
Yue FE; Liu DY; Song J; Zhang LN
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Jun; 19(2):146-8. PubMed ID: 16027782
[TBL] [Abstract][Full Text] [Related]
3. Natural history of chronic hepatitis B REVEALed.
Chen CJ; Yang HI
J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
[TBL] [Abstract][Full Text] [Related]
4. Soluble human leukocyte antigen-G expression in hepatitis B virus infection and hepatocellular carcinoma.
Park Y; Park Y; Lim HS; Kim YS; Hong DJ; Kim HS
Tissue Antigens; 2012 Feb; 79(2):97-103. PubMed ID: 22136460
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B surface antigen-negative, but HBV DNA-positive patients in Bangladesh.
Mahtab MA; Akbar SM; Rahman S
Bangladesh Med Res Counc Bull; 2012 Dec; 38(3):104-7. PubMed ID: 23540186
[TBL] [Abstract][Full Text] [Related]
6. Serum soluble death receptor 5 concentration in patients with chronic hepatitis B is associated with liver damage and viral antigen level.
Du J; Wang L; Han J; Gao L; Ma C; Liang X
Clin Biochem; 2012 Jul; 45(10-11):845-7. PubMed ID: 22537456
[TBL] [Abstract][Full Text] [Related]
7. Soluble fibrinogen-like protein 2 levels in patients with hepatitis B virus-related liver diseases.
Van Tong H; Van Ba N; Hoan NX; Binh MT; Quyen DT; Son HA; Van Luong H; Quyet D; Meyer CG; Song LH; Toan NL; Velavan TP
BMC Infect Dis; 2018 Nov; 18(1):553. PubMed ID: 30419833
[TBL] [Abstract][Full Text] [Related]
8. Biochemical, virological, immunological and histopathological features of 702 incidentally detected chronic hepatitis B virus carriers in Bangladesh.
Al-Mahtab M; Akbar SM; Rahman S; Kamal M; Khan MS
Digestion; 2012; 86(1):1-5. PubMed ID: 22688441
[TBL] [Abstract][Full Text] [Related]
9. Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran.
Makvandi M; Soleimani Jelodar R; Samarbafzadeh A; Neisi N; Sharifi Z; Gholampour A; Masjedizadeh A; Shayesteh A
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2125-2129. PubMed ID: 30139211
[TBL] [Abstract][Full Text] [Related]
10. The prognosis and management of inactive HBV carriers.
Invernizzi F; Viganò M; Grossi G; Lampertico P
Liver Int; 2016 Jan; 36 Suppl 1():100-4. PubMed ID: 26725905
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B inactive carriers: clinical course and outcomes.
Tong MJ; Trieu J
J Dig Dis; 2013 Jun; 14(6):311-7. PubMed ID: 23433008
[TBL] [Abstract][Full Text] [Related]
12. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death.
Chen JD; Yang HI; Iloeje UH; You SL; Lu SN; Wang LY; Su J; Sun CA; Liaw YF; Chen CJ;
Gastroenterology; 2010 May; 138(5):1747-54. PubMed ID: 20114048
[TBL] [Abstract][Full Text] [Related]
13. Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels.
Nakazawa T; Shibuya A; Takeuchi A; Shibata Y; Hidaka H; Okuwaki Y; Takada J; Tanaka Y; Watanabe M; Minamino T; Sakurai K; Koizumi W
J Viral Hepat; 2011 Jul; 18(7):e191-9. PubMed ID: 21692932
[TBL] [Abstract][Full Text] [Related]
14. Significant differences in serum activities of matrix metalloproteinase-2 and -9 between HCV- and HBV-infected patients and carriers.
Kuo WH; Chou FP; Lu SC; Chu SC; Hsieh YS
Clin Chim Acta; 2000 Apr; 294(1-2):157-68. PubMed ID: 10727681
[TBL] [Abstract][Full Text] [Related]
15. [Hepatitis B virus genotypes and alanine aminotransferase levels in HBeAg negative patients with chronic hepatitis B and liver cirrhosis].
Li JQ; Zhuang H; Du H; Wang XH; Duan XZ
Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):491-3. PubMed ID: 16042881
[TBL] [Abstract][Full Text] [Related]
16. Association between TRAIL expression on peripheral blood lymphocytes and liver damage in chronic hepatitis B.
Chen GY; He JQ; Lu GC; Li MW; Xu CH; Fan WW; Zhou C; Chen Z
World J Gastroenterol; 2005 Jul; 11(26):4090-3. PubMed ID: 15996036
[TBL] [Abstract][Full Text] [Related]
17. NIH consensus development statement on management of hepatitis B.
Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
[TBL] [Abstract][Full Text] [Related]
18. Comparison of genotypes C and D of the hepatitis B virus in Japan: a clinical and molecular biological study.
Duong TN; Horiike N; Michitaka K; Yan C; Mizokami M; Tanaka Y; Jyoko K; Yamamoto K; Miyaoka H; Yamashita Y; Ohno N; Onji M
J Med Virol; 2004 Apr; 72(4):551-7. PubMed ID: 14981757
[TBL] [Abstract][Full Text] [Related]
19. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus.
Song le H; Binh VQ; Duy DN; Bock TC; Kremsner PG; Luty AJ; Mavoungou E
J Med Virol; 2004 Jun; 73(2):244-9. PubMed ID: 15122799
[TBL] [Abstract][Full Text] [Related]
20. Promoting effect of hepatitis B virus on the expressoin of phospholipase A2 group IIA.
Zhu C; Song H; Shen B; Wu L; Liu F; Liu X
Lipids Health Dis; 2017 Jan; 16(1):5. PubMed ID: 28077172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
